142 related articles for article (PubMed ID: 34495479)
1. Skin care advice to patients with multiple sclerosis on Fingolimod treatment at increased risk of skin malignancy-room for improvement?
O'Higgins L; Gaughan M; McGuigan C; Lally A
Ir J Med Sci; 2022 Aug; 191(4):1683-1685. PubMed ID: 34495479
[TBL] [Abstract][Full Text] [Related]
2. Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports.
Kum YE; Pamukçu Ö; Canpolat M
Cardiol Young; 2023 Nov; 33(11):2384-2386. PubMed ID: 37170775
[TBL] [Abstract][Full Text] [Related]
3. Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
Gibson S; Mcgraw C
Neurology; 2024 Jan; 102(2):e208027. PubMed ID: 38165340
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center.
Boziki M; Bakirtzis C; Giantzi V; Sintila SA; Kallivoulos S; Afrantou T; Nikolaidis I; Ioannidis P; Karapanayiotides T; Koutroulou I; Parissis D; Grigoriadis N
Front Neurol; 2021; 12():699844. PubMed ID: 34497577
[No Abstract] [Full Text] [Related]
5. Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
Bosco-Lévy P; Debouverie M; Brochet B; Guillemin F; Louapre C; Maillart E; Heinzlef O; Lignot S; Diez P; Abouelfath A; Lassalle R; Blin P; Droz-Perroteau C
Br J Clin Pharmacol; 2022 Mar; 88(3):1268-1278. PubMed ID: 34505304
[TBL] [Abstract][Full Text] [Related]
6. Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis.
Parks NE; Andreou P; Marrie RA; Fisk JD; Bhan V; Kirkland SA
Mult Scler Relat Disord; 2021 Nov; 56():103249. PubMed ID: 34517192
[TBL] [Abstract][Full Text] [Related]
7. Graves' disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis.
Duarte DB; Silva AMD; Freitas C; Cardoso H
Endocr Regul; 2021 Sep; 55(3):169-173. PubMed ID: 34523298
[No Abstract] [Full Text] [Related]
8. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
Sriwastava S; Kataria S; Srivastava S; Kazemlou S; Gao S; Wen S; Saber H; Tripathi R; Sheikh Z; Peterson S; Gwinn R; Bernitsas E
J Neuroimmunol; 2021 Nov; 360():577721. PubMed ID: 34547511
[TBL] [Abstract][Full Text] [Related]
9. Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis.
Grahl S; Bussas M; Wiestler B; Eichinger P; Gaser C; Kirschke J; Zimmer C; Berthele A; Hemmer B; Mühlau M
Neurotherapeutics; 2021 Oct; 18(4):2589-2597. PubMed ID: 34561843
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis.
Cellerino M; Boffa G; Lapucci C; Tazza F; Sbragia E; Mancuso E; Bruschi N; Minguzzi S; Ivaldi F; Poirè I; Laroni A; Mancardi G; Capello E; Uccelli A; Novi G; Inglese M
Neurotherapeutics; 2021 Oct; 18(4):2579-2588. PubMed ID: 34553320
[TBL] [Abstract][Full Text] [Related]
11. Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis.
Correale J; Halfon MJ; Jack D; Rubstein A; Villa A
Mult Scler Relat Disord; 2021 Nov; 56():103264. PubMed ID: 34547609
[TBL] [Abstract][Full Text] [Related]
12. Erratum to "A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod".
Ther Adv Neurol Disord; 2021; 14():17562864211044631. PubMed ID: 34539815
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
[TBL] [Abstract][Full Text] [Related]
14. Proinflammatory CD20
Quendt C; Ochs J; Häusser-Kinzel S; Häusler D; Weber MS
Ann Neurol; 2021 Nov; 90(5):834-839. PubMed ID: 34516013
[TBL] [Abstract][Full Text] [Related]
15. Adherence and persistence in the use of statins and ezetimibe over 8 years in a real-life study.
Santoleri F; Romagnoli A; Costantini A
Curr Med Res Opin; 2021 Dec; 37(12):2061-2066. PubMed ID: 34515600
[TBL] [Abstract][Full Text] [Related]
16. Vaccine hesitancy among people with multiple sclerosis.
Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
[TBL] [Abstract][Full Text] [Related]
17. The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis.
Asha MZI; Al-Asaad Y; Khalil SFH
IBRO Neurosci Rep; 2021 Dec; 11():103-111. PubMed ID: 34505112
[TBL] [Abstract][Full Text] [Related]
18. Acute renal failure due to rhabdomyolysis in relation to abiraterone and rosuvastatin.
Cintra M; Pedraza Cezón LA; Martín Navarro JA; Torres Aguilera E; Albalate Ramón M; Alcázar Arroyo R; Procaccini F; Puerta Carretero M; Ortega Díaz M; Medina Zahonero L; Jaldo Rodríguez MT; de Sequera P
Nefrologia (Engl Ed); 2021 Sep; ():. PubMed ID: 34503863
[No Abstract] [Full Text] [Related]
19. Can direct oral anticoagulants be used in kidney transplant recipients?
Parker K; Chu J; Morton M; Bhutani S; Picton M; Mitra S; Thachil J
Clin Transplant; 2021 Dec; 35(12):e14474. PubMed ID: 34498777
[TBL] [Abstract][Full Text] [Related]
20. Smoldering lesions in MS: if you like it then you should put a rim on it.
Pinto C; Cambron M; Dobai A; Vanheule E; Casselman JW
Neuroradiology; 2022 Apr; 64(4):703-714. PubMed ID: 34498108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
